EP Patent

EP4199968A1 — Antibody-tlr agonist conjugates, methods and uses thereof

Assigned to Ambrx Inc · Expires 2023-06-28 · 3y expired

What this patent protects

Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.

USPTO Abstract

Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4199968A1
Jurisdiction
EP
Classification
—
Expires
2023-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Ambrx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.